NYSE:CRL

Charles River Laboratories International Stock Forecast, Price & News

$226.32

+5.74 (+2.60%)

(As of 06/24/2022 06:40 PM ET)

Add

Compare

Today's Range: $220.23
▼
$226.43
50-Day Range: $204.13
▼
$296.85
52-Week Range: $203.37
▼
$460.21

Volume: 497,100 shs
Average Volume: 545,073 shs
Market Capitalization: $11.50 billion

P/E Ratio: 27.57
Dividend Yield: N/A
Price Target: $381.00

30 days | 90 days | 365 days | Advanced Chart

Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock Forecast (MarketRank)

Overall MarketRank^™

2.41 out of 5 stars

Medical Sector

198th out of 1,411 stocks

Commercial Physical Research Industry

3rd out of 24 stocks

3.4 Analyst's Opinion

Consensus Rating
Charles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $381.00, Charles River Laboratories International has a forecasted upside of 68.3% from its current price of $226.32.
Amount of Analyst Coverage
Charles River Laboratories International has only been the subject of 4 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Charles River Laboratories International has received 462 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Charles River Laboratories International has received 257 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Charles River Laboratories International has received 64.26% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote “Outperform” if you believe CRL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Charles River Laboratories International does not currently pay a dividend.
Dividend Growth
Charles River Laboratories International does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,111.00 in company stock.
Percentage Held by Insiders
Only 1.10% of the stock of Charles River Laboratories International is held by insiders.
Percentage Held by Institutions
93.06% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Charles River Laboratories International are expected to grow by 15.26% in the coming year, from $11.60 to $13.37 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Charles River Laboratories International is 27.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.09.
Price to Earnings Ratio vs. Sector
The P/E ratio of Charles River Laboratories International is 27.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 15.72.
Price to Earnings Growth Ratio
Charles River Laboratories International has a PEG Ratio of 1.39. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Charles River Laboratories International has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

June 23, 2022 | finance.yahoo.com

Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

June 15, 2022 | americanbankingnews.com

Charles River Laboratories International, Inc. (NYSE:CRL) to Post Q2 2022 Earnings of $2.75 Per Share, KeyCorp Forecasts

June 13, 2022 | seekingalpha.com

Charles River, ASC Therapeutics to make gene therapy ASC618 for treatment of hemophilia A

June 12, 2022 | americanbankingnews.com

Charles River Laboratories International (NYSE:CRL) Sets New 12-Month Low at $215.57

June 11, 2022 | americanbankingnews.com

Charles River Laboratories International, Inc. (NYSE:CRL) to Post FY2022 Earnings of $11.54 Per Share, KeyCorp Forecasts

June 10, 2022 | americanbankingnews.com

Charles River Laboratories International (NYSE:CRL) Shares Gap Down to $247.21

June 8, 2022 | americanbankingnews.com

Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of "Buy" by Analysts

June 3, 2022 | finance.yahoo.com

Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

May 24, 2022 | markets.businessinsider.com

Analyst Ratings for Charles River

May 24, 2022 | finance.yahoo.com

Charles River Laboratories International, Inc.'s (NYSE:CRL) Intrinsic Value Is Potentially 87% Above Its Share Price

May 4, 2022 | seekingalpha.com

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q1 2022 Earnings Call Transcript

May 4, 2022 | seekingalpha.com

Charles River Laboratories Non-GAAP EPS of $2.75 beats by $0.03, revenue of $913.9M beats by $5.26M; updates FY22 guidance

May 4, 2022 | apnews.com

Charles River Laboratories Announces First-Quarter 2022 Results

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Commercial physical research
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NYSE:CRL
CUSIP: 15986410
CIK: 1100682
Web: www.criver.com
Phone: (781) 222-6000
Fax: 978-988-5665
Employees: 20,000
Year Founded: 1947

Company Calendar

Last Earnings: 5/04/2022
Today: 6/27/2022
Next Earnings (Estimated): 8/03/2022
Fiscal Year End: 12/31/2022

Price Target and Rating

Average Stock Price Forecast: $381.00
High Stock Price Forecast: $480.00
Low Stock Price Forecast: $280.00
Forecasted Upside/Downside: +68.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78571428571429
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.21
Trailing P/E Ratio: 27.57
Forward P/E Ratio: 19.51
P/E Growth: 1.39
Net Income: $390.98 million
Net Margins: 11.64%
Pretax Margin: 14.47%
Return on Equity: 21.90%
Return on Assets: 7.78%

Debt

Debt-to-Equity Ratio: 1.02
Current Ratio: 1.34
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: $35.40 billion
Price / Sales: 0.32
Cash Flow: $15.77 per share
Price / Cash Flow: 14.35
Book Value: $50.29 per share
Price / Book: 4.50

Miscellaneous

Outstanding Shares: 50,805,000
Free Float: 50,246,000
Market Cap: $11.50 billion
Optionable: Optionable
Beta: 1.27

Social Links

Charles River Laboratories International Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International or view top-rated stocks.
What is Charles River Laboratories International's stock price forecast for 2022?: 14 brokers have issued twelve-month price objectives for Charles River Laboratories International's stock. Their CRL stock forecasts range from $280.00 to $480.00. On average, they anticipate Charles River Laboratories International's share price to reach $381.00 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price.
View analysts' price targets for Charles River Laboratories International or view top-rated stocks among Wall Street analysts.
How has Charles River Laboratories International's stock price performed in 2022?: Charles River Laboratories International's stock was trading at $376.78 at the beginning of 2022. Since then, CRL shares have decreased by 39.9% and is now trading at $226.32.
View the best growth stocks for 2022 here.
When is Charles River Laboratories International's next earnings date?: Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Charles River Laboratories International.
How were Charles River Laboratories International's earnings last quarter?: Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings results on Wednesday, May, 4th. The medical research company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of $2.71 by $0.04. The medical research company earned $913.93 million during the quarter, compared to analyst estimates of $908.64 million. Charles River Laboratories International had a net margin of 11.64% and a trailing twelve-month return on equity of 21.90%. The business's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.53 earnings per share.
View Charles River Laboratories International's earnings history.
What guidance has Charles River Laboratories International issued on next quarter's earnings?: Charles River Laboratories International updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $11.50-$11.75 for the period, compared to the consensus EPS estimate of $11.64. The company issued revenue guidance of $4.02 billion-$4.09 billion, compared to the consensus revenue estimate of $4.02 billion.
Who are Charles River Laboratories International's key executives?: Charles River Laboratories International's management team includes the following people:
Mr. James C. Foster J.D., Chairman, CEO & Pres (Age 71, Pay $3.28M) (LinkedIn Profile)
Ms. Birgit Girshick, Corp. Exec. VP & COO (Age 52, Pay $1.18M) (LinkedIn Profile)
Mr. Joseph W. LaPlume, Corp. Exec. VP of Corp. Devel. & Strategy (Age 48, Pay $1.07M) (LinkedIn Profile)
Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 61, Pay $1.13M) (LinkedIn Profile)
Mr. David Ross Smith, Sr. Financial Advisor (Age 56, Pay $1.38M) (LinkedIn Profile)
Ms. Flavia H. Pease, Corp. Exec. VP & CFO
Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 45) (LinkedIn Profile)
Prof. Julie Frearson Ph.D., Corp. Sr. VP & Chief Scientific Officer
Mr. Mark Mintz, Corp. Sr. VP & Chief Information Officer
Todd Spencer, Corp. VP of Investor Relations
What is James C. Foster's approval rating as Charles River Laboratories International's CEO?: 291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.
Who are some of Charles River Laboratories International's key competitors?: Some companies that are related to Charles River Laboratories International include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Illumina (ILMN), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of CRL's competitors.
What other stocks do shareholders of Charles River Laboratories International own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?: Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
Who are Charles River Laboratories International's major shareholders?: Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.68%), BlackRock Inc. (10.29%), State Street Corp (3.98%), Clearbridge Investments LLC (2.69%), Massachusetts Financial Services Co. MA (2.25%) and William Blair Investment Management LLC (2.04%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends for Charles River Laboratories International.
Which institutional investors are selling Charles River Laboratories International stock?: CRL stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Brown Advisory Inc., Echo Street Capital Management LLC, Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., Eaton Vance Management, Raymond James & Associates, and First Trust Advisors LP. Company insiders that have sold Charles River Laboratories International company stock in the last two years include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Stephen D Chubb, Victoria L Creamer, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International or view top insider-selling stocks.
Which institutional investors are buying Charles River Laboratories International stock?: CRL stock was bought by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Clearbridge Investments LLC, First Republic Investment Management Inc., BlackRock Inc., Montrusco Bolton Investments Inc., Viking Global Investors LP, Baird Financial Group Inc., and Riverbridge Partners LLC.
View insider buying and selling activity for Charles River Laboratories International or or view top insider-buying stocks.
How do I buy shares of Charles River Laboratories International?: Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Charles River Laboratories International's stock price today?: One share of CRL stock can currently be purchased for approximately $226.32.
How much money does Charles River Laboratories International make?: Charles River Laboratories International (NYSE:CRL) has a market capitalization of $11.50 billion and generates $35.40 billion in revenue each year. The medical research company earns $390.98 million in net income (profit) each year or $8.21 on an earnings per share basis.
How many employees does Charles River Laboratories International have?: Charles River Laboratories International employs 20,000 workers across the globe.
Does Charles River Laboratories International have any subsidiaries?: The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More
When was Charles River Laboratories International founded?: Charles River Laboratories International was founded in 1947.
How can I contact Charles River Laboratories International?: Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for Charles River Laboratories International is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at [email protected], or via fax at 978-988-5665.

This page (NYSE:CRL) was last updated on 6/27/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Charles River Laboratories International Stock Forecast, Price & News

Receive CRL Stock News and Ratings via Email

CRL Stock Forecast (MarketRank)

Overall MarketRank™

3.4 Analyst's Opinion

4.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

2.5 Company Ownership

1.9 Earnings and Valuation

About Charles River Laboratories International (NYSE:CRL)

CRL Stock News Headlines

Industry, Sector and Symbol

Company Calendar

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Charles River Laboratories International Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

What is Charles River Laboratories International's stock price forecast for 2022?

How has Charles River Laboratories International's stock price performed in 2022?

When is Charles River Laboratories International's next earnings date?

How were Charles River Laboratories International's earnings last quarter?

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Who are Charles River Laboratories International's key executives?

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

Who are some of Charles River Laboratories International's key competitors?

What other stocks do shareholders of Charles River Laboratories International own?

What is Charles River Laboratories International's stock symbol?

Who are Charles River Laboratories International's major shareholders?

Which institutional investors are selling Charles River Laboratories International stock?

Which institutional investors are buying Charles River Laboratories International stock?

How do I buy shares of Charles River Laboratories International?

What is Charles River Laboratories International's stock price today?

How much money does Charles River Laboratories International make?

How many employees does Charles River Laboratories International have?

Does Charles River Laboratories International have any subsidiaries?

When was Charles River Laboratories International founded?

How can I contact Charles River Laboratories International?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™